Observational studyJournal of neurology, neurosurgery, and psychiatry2023

Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses.

Frederik Novak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.